Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Stephens

Analysts at Stephens initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report issued on Monday, Marketbeat reports. The brokerage set an “overweight” rating and a $65.00 price target on the stock. Stephens’ price objective would indicate a potential upside of 51.73% from the stock’s current price.

Other equities analysts have also issued reports about the company. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a report on Monday, August 26th. Truist Financial reaffirmed a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Oppenheimer raised their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Finally, Guggenheim raised their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.13.

Kymera Therapeutics Trading Up 1.0 %

Shares of NASDAQ KYMR opened at $42.84 on Monday. The stock has a fifty day simple moving average of $47.02 and a two-hundred day simple moving average of $41.80. Kymera Therapeutics has a 1-year low of $18.89 and a 1-year high of $53.27. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of -18.31 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same period in the prior year, the company earned ($0.90) earnings per share. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. Analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after purchasing an additional 996,300 shares in the last quarter. FMR LLC raised its position in Kymera Therapeutics by 5.8% during the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock valued at $241,816,000 after purchasing an additional 282,301 shares in the last quarter. Vanguard Group Inc. raised its position in Kymera Therapeutics by 19.2% during the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after purchasing an additional 769,486 shares in the last quarter. Wellington Management Group LLP raised its position in Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after purchasing an additional 308,954 shares in the last quarter. Finally, Avoro Capital Advisors LLC raised its position in Kymera Therapeutics by 3.0% during the first quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock valued at $156,333,000 after purchasing an additional 113,888 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.